Summary
Xortx Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 162 | $351.54 | $345.06 | -$6.48 | -1.84% |
 Kevin Bresler TD Waterhouse Canada Inc. | 9 | $19 | $19.08 | $0.08 | 0.42% |
Xortx Therapeutics Inc. (XRTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Xortx Therapeutics Inc. ever had a stock split?
Xortx Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Allen Warren Davidoff CEO | NASDAQ (CM) Exchange | 98420Q405 CUSIP |
| CA Country | 2 Employees | - Last Dividend | 27 Mar 2026 Last Split | - IPO Date |
Overview
XORTX Therapeutics Inc. is a distinguished late stage clinical pharmaceutical company focused on inventing and marketing innovative therapies for a range of significant health issues related to kidney disease and metabolic disorders. With its operations deeply rooted in Alberta Beach, Canada, XORTX operates at the forefront of addressing progressive kidney diseases, including conditions such as pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection-related kidney injuries. The company's strategic partnerships with leading research institutions like the Icahn School of Medicine and the University of Florida Research Foundation, Inc., underscore its commitment to groundbreaking research and therapeutic development.
Products and Services
- XRx-008:
- XRx-101:
- XRX-225:
This is XORTX’s late clinical stage program aimed at treating autosomal dominant polycystic kidney disease (ADPKD). By focusing on this genetic disorder, XRx-008 represents a significant advancement in the therapeutic landscape for patients suffering from ADPKD, a condition that profoundly affects kidney function over time.
Developed for the treatment of acute kidney injury (AKI) associated with respiratory virus infections and its subsequent health consequences, XRx-101 addresses a critical need for treatments that can mitigate the renal damage caused by viral infections. This program underlines the company's broader commitment to tackling kidney injuries, stemming not just from chronic conditions but acute infections as well.
This program is tailored for the treatment of type 2 diabetic nephropathy, a common complication of diabetes that leads to chronic kidney disease. XRX-225 aims to alleviate the progression of kidney damage in patients with type 2 diabetes, underscoring XORTX's focus on metabolic disorders that significantly impact kidney health.
